Want to join the conversation?
$REGN 2Q15 Call: For Sarilumab, REGN reported positive data from three additional Phase 3 trials, including the SARIL-RA target study of Sarilumab in combination with non-biological disease modifying anti-rheumatic drugs or DMARD therapy. On track to submit BLA in the US by year-end and regulatory submission in Europe towards the end of next year.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.